Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 9, Issue 2, Pages 169-186Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2016.1124757
Keywords
Hepcidin; ferroportin; anemia of chronic disease; iron overload; iron deficiency; clinical trials
Categories
Funding
- US National Institutes of Health [R01 CA188025, R01 CA171101, T90 DE021989]
- AbbVie
Ask authors/readers for more resources
The secreted peptide hormone hepcidin regulates systemic and local iron homeostasis through degradation of the iron exporter ferroportin. Dysregulation of hepcidin leads to altered iron homeostasis and development of pathological disorders including hemochromatosis, and iron loading and iron restrictive anemias. Therapeutic modulation of hepcidin is a promising method to ameliorate these conditions. Several approaches have been taken to enhance or reduce the effects of hepcidin in vitro and in vivo. Based on these approaches, hepcidin modulating drugs have been developed and are undergoing clinical evaluation. In this article we review the rationale for development of these drugs, the data concerning their safety and efficacy, their therapeutic uses, and potential future prospects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available